Atlanta、GAにおける乳がんの臨床試験
Atlantaとその周辺地域（約30マイル以内）の拠点で、乳がんに関する41件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Atlanta Cancer Care - Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Atlanta VA Medical Center, Decatur · 6マイル先
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- Winship Cancer Institute, Emory University, Atlanta
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
被験者募集中第3相
- Emory Proton Therapy Center, Atlanta
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
被験者募集中第3相
- Emory University Hospital, Atlanta
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Emory University Winship Cancer Institute, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- Winship Cancer Institute, Atlanta
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
被験者募集中第1/2相
- Winship Cancer Institute of Emory University, Atlanta
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
被験者募集中第2相
- Emory University (Data Collection Only), Atlanta
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- Winship Cancer Institute of Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
被験者募集中第2相
- Emory University, Atlanta
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Winship Cancer Institute of Emory University, Atlanta
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- 他5件
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
被験者募集中第1相
- Emory University - Winship Cancer Institute, Atlanta
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
被験者募集中健康なボランティア歓迎
- Emory University Hospital/Winship Cancer Institute, Atlanta
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
被験者募集中第1相
- Emory University, Atlanta
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
被験者募集中第2相
- Winship Cancer Institute at Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Northside Hospital, Atlanta
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 他2件
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
被験者募集中第1/2相
- Emory University, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Winship Cancer Institute, Emory University, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Winship Cancer Institute, Emory University, Atlanta
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
被験者募集中第2相
- GSK Investigational Site, Atlanta
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
被験者募集中第3相
- Emory University School of Medicine, Atlanta
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
被験者募集中健康なボランティア歓迎
- Emory University Hospital/Winship Cancer Institute, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
被験者募集中観察研究健康なボランティア歓迎
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- Winship Cancer Institute of Emory University, Atlanta
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Emory University Hospital Midtown, Atlanta
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
被験者募集中第2相
- Emory University Winship Cancer Institute, Atlanta
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- 他5件
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 111, Atlanta
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Emory Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Northside Hospital, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
被験者募集中第1相
- Emory University, Winship Cancer Institute, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
被験者募集中第1相
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 他1件
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Atlanta
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
被験者募集中観察研究
- Piedmont Cancer Institute, Atlanta
- Emory University - Winship Cancer Institute, Atlanta
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Atlantaにおける他の研究
- がん（全種類）49件の研究
- 非小細胞肺癌47件の研究
- 多発性骨髄腫42件の研究
- 前立腺がん33件の研究
- 急性骨髄性白血病31件の研究
- 卵巣がん29件の研究
- 大腸癌29件の研究
- 肺がん29件の研究
- 転移性癌28件の研究
- 大うつ病性障害25件の研究
- 心不全25件の研究
- 頭頸部扁平上皮癌24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。